Ads
related to: sluggish cognitive tempo disorder symptoms in children
Search results
Results From The WOW.Com Content Network
In April 2014, The New York Times reported that sluggish cognitive tempo is the subject of pharmaceutical company clinical drug trials, including ones by Eli Lilly that proposed that one of its biggest-selling drugs, Strattera, could be prescribed to treat proposed symptoms of sluggish cognitive tempo. [57]
Atomoxetine is sometimes used in the treatment of cognitive impairment and frontal lobe symptoms due to conditions like traumatic brain injury (TBI). [48] [49] It is used to treat ADHD-like symptoms such as sustained attentional problems, disinhibition, [50] lack of arousal, fatigue, and depression, including symptoms from cognitive disengagement syndrome. [48]
He proposed the renaming of sluggish cognitive tempo to cognitive disengagement syndrome (CDS). [7] Besides his clinical work, he is also an expert in the neuropsychology of executive function and self-regulation. He is board certified in three clinical specialties: clinical neuropsychology, clinical psychology, and clinical child and ...
The Child and Adolescent Symptom Inventory (CASI) is a behavioral rating checklist created by Kenneth Gadow and Joyce Sprafkin that evaluates a range of behaviors related to common emotional and behavioral disorders identified in the Diagnostic and Statistical Manual of Mental Disorders (DSM), including attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder ...
The emerging concept of sluggish cognitive tempo has also been implicated in the expression of brain fog symptoms. [42] Patients recovering from COVID-19 report experiencing brain fog, which can reflect a wide variety of neurological and psychological symptoms linked to COVID-19. [43]
As of April 14th, 2014, the statement under SCT under History that "As of April 2014, sluggish cognitive tempo is the subject of pharmaceutical company clinical drug trials, including ones by Eli Lilly that proposed that Strattera could be prescribed to treat proposed symptoms of sluggish cognitive tempo.[4]" is false.
To put that in perspective, two of the newer medications, lecanemab and donanemab, have been shown to moderately slow a decline in memory and thinking abilities — by 27.1% and 22.3% ...
Disorders of diminished motivation (DDM) is an umbrella term referring to a group of psychiatric and neurological disorders involving diminished capacity for motivation, will, and affect. [1] [2] [3] [4]